Fig. 3: BRAF inhibition alters the FGF pathway.

a Alterations of mRNA levels of indicated FGFR ligands, as measured by human growth factor PCR array, after treatment of M14, UACC-62, and A375 for 3 days with vemurafenib (0.5 μM). b Secretion of FGF1 and FGF7 in A375 cells treated with vemurafenib for 3 days (0.5 µM). Samples were measured by ELISA and are derived from two (FGF1) to three (FGF7) independent experiments. c Analysis of FGF1 expression in the publicly available data set GSE20051 (n = 5) of melanoma cells exposed to 0.25 µM PLX4032 (vemurafenib) for 8 h. In the boxplot figure, the median value (in the box), the first and third quartile (upper and lower border of the box), and the minimum values are indicated. Maximum values are represented as outliers. d Real-time PCR of FGF1 in indicated melanoma cell lines after 24 h of treatment with vemurafenib (0.5 µM) or the MEK inhibitors PD184352 (2 µM) or trametinib (50 nM). Data are derived from 2–5 independent experiments, each performed in triplicate, and are referred to control cells treated with the solvent DMSO. *p > 0.05; **p > 0.01